Vazosan (1.25mg) bank 30tab * 120mg
DESCRIPTION
Vazosan is a drug for the treatment and prevention of chronic heart failure in dogs and blood pressure control in cats. Dosage form: tablets from light yellow to light brown for oral administration.
COMPOSITION
Vazosan-1.25 in one tablet contains 1.25mg of ramipril as an active ingredient, and as auxiliary substances: lactose - 74.55mg, microcrystalline cellulose - 31.9mg, starch - 6mg, calcium stearate - 2.4mg, talc - 2.4mg, colloidal silicon dioxide - 1.2mg and iron oxide - 0.3mg.
PHARMACOLOGICAL PROPERTIES
Vasosan belongs to the pharmacological group: angiotensin converting enzyme (ACE) inhibitors.
Ramipril, which is part of Vasosan, is an antihypertensive agent that, by suppressing the synthesis of angiotensin II, reduces its vasoconstrictor effect and its stimulating effect on aldosterone secretion, and also inhibits the breakdown of bradykinin. Vasosan reduces the total vascular peripheral resistance, does not significantly alter renal blood flow (and in some cases increases it) and glomerular filtration rate. Vasosan has a hypotensive effect without causing compensatory tachycardia. After a single dose of Vazosan, the hypotensive effect reaches a maximum after 1 - 3 hours and lasts for 24 hours. With daily administration of Vazosan, the hypotensive effect gradually increases over 3 - 4 weeks and remains at this level during the treatment period.
Vasosan also has a cardioprotective effect by inhibiting the angiotensin-converting enzyme in the myocardium and accumulating bradykinin.
After oral administration of Vazosan, ramipril is rapidly absorbed in an amount of at least 50-60% of the dose taken. The primary metabolism of ramipril occurs in the liver. This forms a pharmacologically active derivative of ramipril - ramiprilat. Ramiprilat is 6 times more active than ramipril in inhibiting angiotesin-converting enzyme. Plasma protein binding for ramipril is 73%, and for ramiprilat - 56%.
After a daily, single dose of Vazosan, a steady concentration of ramiprilat in plasma is achieved by the 4th day. In dogs, about 60% of the drug is excreted in the urine and about 40% in the faeces (mainly in the form of metabolites).
In cats, ramipril is excreted primarily in the feces (85% to 89%) and to a lesser extent in urine (9% to 12%).
With impaired renal function, the excretion of ramipril and its metabolites slows down in proportion to the decrease in creatinine clearance.
According to the degree of impact on the body, Vazosan belongs to the group of low-hazard substances (hazard class 4 according to GOST 12.1.007-76).
Diuretics and a diet with a low sodium content enhance the effect of ACE inhibitors, therefore, during treatment with Vasosan, do not use increased doses of diuretics and a low sodium diet to prevent the development of hypotension and acute renal failure.
The simultaneous use of Vazosan with potassium-sparing diuretics can lead to hyperkalemia. If necessary, the combined use of these drugs is recommended to consult with your doctor to control plasma potassium.
The combination of ACE inhibitors with NSAIDs (non-steroidal anti-inflammatory drugs) can lead to impaired blood pressure due to changes in glomerular filtration, which can lead to acute renal failure.
INDICATIONS
Vasosan is used in dogs with chronic heart failure, with arterial hypertension, with cardiomyopathies of various origins and for the prevention of myocardial ischemia. For cats, the drug is used to lower systolic pressure (if the systolic pressure is between 160 and 230 mm Hg).
APPLICATION
The drug is given orally once a day, on an empty stomach. The initial therapeutic dose for animals per day is 0.125 mg of ramipril per 1 kg of animal weight. Large dogs (weight over 50 kg) can be given a daily dose of the drug in two doses. The animal must be accurately weighed before calculating the dose.
In the absence of the effect of lowering blood pressure while taking Vazosan, you can increase the daily dose to 0.25 mg / kg of animal weight or include diuretic drugs in conventional doses in the treatment regimen to enhance the therapeutic effect.
In case of congestion in the lungs, two weeks after starting the use of the drug, the daily dose can be increased to 0.25 mg per 1 kg of animal weight.
Vasosan is prescribed to cats if the cause of the high blood pressure (eg, hyperthyroidism) cannot be eliminated. Treatment with Vazosan should be carried out under the regular supervision of a veterinarian (1 time in 7 to 10 days).
In cats with severe eye damage or rapidly progressive neurologic symptoms (due to increased blood pressure), a clinical assessment is recommended every 1 to 3 days.
The duration of treatment with Vazosan is determined by the veterinarian.
Avoid skipping the next dose of the drug, as this can lead to a decrease in therapeutic effectiveness. If one dose is missed, the use of the drug is resumed in the same dosage and according to the same scheme.
SPECIAL INSTRUCTIONS
At the beginning of treatment with ACE inhibitors or after increasing the dose, in rare cases, lethargy, apathy or ataxia may appear. In this case, treatment should be discontinued and, if necessary, symptomatic treatment should be prescribed. Once the animal has stabilized, treatment can be continued with half the initial dose.
The use of an ACE inhibitor in animals with symptoms of hypovolemia and dehydration can lead to the development of acute hypotension. In such cases, it is necessary to restore the water-salt balance in the animal's body and postpone the use of Vazosan until the condition stabilizes.
For animals at risk of developing hypovolemia, treatment with Vazosan is started with a half dose, which is given for a week.
Animals that have an increased risk of developing excessive hypotension after taking the first dose, as well as after increasing the dose of the drug, should be under strict medical supervision, especially in the first 2 weeks of treatment.
Application of Vazosan to animals with impaired renal function is carried out under the constant supervision of a veterinarian.
Sudden drug withdrawal does not lead to a rapid increase in blood pressure.
In case of allergic reactions, the use of the drug is stopped and symptomatic treatment is carried out.
For pregnant and lactating females, the drug can be used after consulting a veterinarian.
The day before anesthesia or deep anesthesia, it is recommended to stop taking Vazosan, since anesthetics have a hypotensive effect.
CONTRAINDICATIONS
Contraindication to the use of Vazosan is individual hypersensitivity to the drug components, decompensated liver and kidney failure, as well as lactation and pregnancy of animals. The drug is not used in dogs for mitral valve stenosis, aortic stenosis and obstructive hypertrophic cardiomyopathy Vasosan is not intended for use in productive animals.
OVERDOSE
Exceeding the dosage by more than 20 times (2.5 mg / kg of animal weight) does not cause clinical changes in healthy animals. In rare cases, there are signs of hypotension, manifested in the form of apathy and ataxia.
SIDE EFFECTS
Possible side reactions - a decrease in pressure, accompanied by fatigue, lethargy or ataxia; possible sinusitis, rhinitis, bronchospasm - from the respiratory tract; nausea, dyspepsia, vomiting, diarrhea, constipation, dysphagia, loss of appetite - from the gastrointestinal tract; convulsions, neuralgia, neuropathy, paresthesia, tremor - from the nervous system.
If a side effect occurs, the use of Vazosan should be discontinued and a veterinarian should be consulted. When resuming treatment, use a dose that is half of the initial one.
PRECAUTIONS
When working with Vazosan, you should follow the general rules of personal hygiene and safety measures provided for when working with medicines. At the end of work, hands should be washed with warm water and soap.
People with hypersensitivity to the drug components should avoid direct contact with Vasosan. It is forbidden to use empty packaging from under the medicinal product for household purposes, it must be disposed of with household waste. Unused medicinal product is disposed of in accordance with legal requirements.
SHELF LIFE AND STORAGE
Store the drug in the manufacturer's closed packaging, protected from direct sunlight, separately from food and feed, at a temperature of 2 В° C to 30 В° C. The shelf life of the medicinal product, subject to storage conditions in the manufacturer's closed packaging, is 3 years from the date of manufacture. It is necessary to close the caps tightly after each opening of the bottle. Do not use the drug after the expiration date.
PACKAGING
The drug is produced packaged in 30 tablets in polymer bottles with plastic tight-fitting lids.
Specifications
KolVUP
five
Manufacturer
APICENNA
Temperature regime
from +3 to +30
Teaser
drug for the treatment and prevention of chronic heart failure in dogs and blood pressure control in cats